2016
DOI: 10.1002/elps.201600061
|View full text |Cite
|
Sign up to set email alerts
|

Thrombin generation assay in untreated whole human blood

Abstract: Present coagulation assays fail to detect mild coagulation disorders, while thrombin-generation (TG) assays solve this problem. However, most of them only work with threated blood samples, which makes them labor intensive, time consuming, unreliable, and expensive. We have developed a TG electrophoretic assay that uses a thrombin specific charge-changing fluorescent peptide substrate, electrophoretic separation, and requires a drop of blood. The limit of detection of the assay was 1.97 nM in phosphate buffer s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…Global screening assays for coagulopathy are regaining interest as point-of-care tests (POCT) based on their ability to mutually analyse the impact of plasmatic and cellular factors, such as platelets, white blood cells and erythrocytes. Thromboelastrometry (ROTEM) (ROTEM delta, TEM, Munich, Germany), Thromboelastography (TEG) (Haemonetics S.A., Signy, Switzerland), Sonoclot (Sienco Inc., Morrison, CO, USA) coagulation analysis [2, 5, 6], whole blood aggregation [7], whole blood thrombin generation [8] and clot waveform analysis testing [9] have the potential to dramatically change our current analytical approach to the assessment of hemostasis, due to their holistic emphasis on the physiology of coagulation. ROTEM and TEG were introduced to clinical practice as a POCT devices [10] and are both used as a diagnostic measure in various bleeding disorders in peri-operative clotting management [11, 12].…”
Section: Introductionmentioning
confidence: 99%
“…Global screening assays for coagulopathy are regaining interest as point-of-care tests (POCT) based on their ability to mutually analyse the impact of plasmatic and cellular factors, such as platelets, white blood cells and erythrocytes. Thromboelastrometry (ROTEM) (ROTEM delta, TEM, Munich, Germany), Thromboelastography (TEG) (Haemonetics S.A., Signy, Switzerland), Sonoclot (Sienco Inc., Morrison, CO, USA) coagulation analysis [2, 5, 6], whole blood aggregation [7], whole blood thrombin generation [8] and clot waveform analysis testing [9] have the potential to dramatically change our current analytical approach to the assessment of hemostasis, due to their holistic emphasis on the physiology of coagulation. ROTEM and TEG were introduced to clinical practice as a POCT devices [10] and are both used as a diagnostic measure in various bleeding disorders in peri-operative clotting management [11, 12].…”
Section: Introductionmentioning
confidence: 99%